Overview

AZD5438 in Patients With Advanced Solid Malignancies

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
0
Participant gender:
All
Summary
Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction with preclinical and the available clinical pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the development of AZD5438 as a potential anti-cancer agent would be discontinued.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Criteria
Inclusion Criteria:

- Advanced solid malignancy

- Cancer refractory to standard treatments or for which no standard therapy exits

Exclusion Criteria:

- Radiotherapy within 3 weeks of the start of treatment

- Investigational product within the last 3 weeks

- Systemic cytotoxic anti-cancer therapy within the last 3 weeks

- Any significant clinical disorder that makes it undesirable for the patient to
participate